Hiroshi Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroshi Sato has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Haruhiko Kondo
Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
1 shared publication - Hirofumi Ogawa
Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka, Japan
1 shared publication - Hirofumi Yasui
Division of Gastrointestinal Oncology, Shizuoka Cancer Center
1 shared publication Tatsuyuki Kawano
Department of Esophago‐Gastric Surgery Tokyo Medical and Dental University 1‐5‐45 Yushima, Bunkyo‐ku Tokyo Japan
1 shared publicationYasuhiro Tsubosa
Division of Esophageal Surgery Shizuoka Cancer Center Hospital 1007 Shimonagakubo, Nagaizumi‐cho 411‐8777 Shizuoka Japan
1 shared publication- Yasuhiro Tsubosa
Division of Esophageal Surgery, Shizuoka Cancer Center, Shizuoka, Japan
1 shared publication
Latest Publications
- 6 January 2012
- Published by Wiley in World Journal of Surgery
- Vol. 36 (3) , 617-622
Correlation Between the Pretherapeutic Neutrophil to Lymphocyte Ratio and the Pathologic Response to Neoadjuvant Chemotherapy in Patients With Advanced Esophageal Cancer
Background: An elevation in the neutrophil‐to‐lymphocyte ratio (NLR) has been shown to be associated with a poorer prognosis in patients with various tumors. The aim of this retrospective study was to clarify the correlation of the pretherapeutic NLR with the prognostic value of the pathologic response to neoadjuvant chemotherapy (NAC) in patients with advanced esophageal cancer.Methods: This study was a retrospective review of 83 patients undergoing NAC for advanced esophageal cancer following esophagectomy. The NLR was measured before NAC, and the pathologic responses to NAC were evaluated.Results: A comparison was performed for those whose pathology responded (responders) (G3/G2/G1b) and nonresponders (G1a/G0). In a univariate analysis, the cStage (P = 0.005), cN (P = 0.0001), and NLR (P = 0.005) were statistically significant parameters. A multivariate analysis revealed that the factors independently associated with pathologic responses were the pretreatment NLR (P = 0.043) and lymph nodes metastasis (P = 0.002). The pretreatment NLR (P = 0.001). The pathologic response rates were 56% in the patients with an NLR <2.2 and 21% in patients with an NLR of ≥2.2.Conclusions: Our study is the first to demonstrate that the pretherapeutic NLR can be used as a predictor for chemosensitivity of thoracic esophageal cancer. Preoperative evaluation based on the clinical N stage and NLR may be easily used in routine clinical practice.
- 6 January 2012
- Published by Wiley in World Journal of Surgery
- Vol. 36 (3) , 617-622
Correlation Between the Pretherapeutic Neutrophil to Lymphocyte Ratio and the Pathologic Response to Neoadjuvant Chemotherapy in Patients With Advanced Esophageal Cancer
Background: An elevation in the neutrophil‐to‐lymphocyte ratio (NLR) has been shown to be associated with a poorer prognosis in patients with various tumors. The aim of this retrospective study was to clarify the correlation of the pretherapeutic NLR with the prognostic value of the pathologic response to neoadjuvant chemotherapy (NAC) in patients with advanced esophageal cancer.Methods: This study was a retrospective review of 83 patients undergoing NAC for advanced esophageal cancer following esophagectomy. The NLR was measured before NAC, and the pathologic responses to NAC were evaluated.Results: A comparison was performed for those whose pathology responded (responders) (G3/G2/G1b) and nonresponders (G1a/G0). In a univariate analysis, the cStage (P = 0.005), cN (P = 0.0001), and NLR (P = 0.005) were statistically significant parameters. A multivariate analysis revealed that the factors independently associated with pathologic responses were the pretreatment NLR (P = 0.043) and lymph nodes metastasis (P = 0.002). The pretreatment NLR (P = 0.001). The pathologic response rates were 56% in the patients with an NLR <2.2 and 21% in patients with an NLR of ≥2.2.Conclusions: Our study is the first to demonstrate that the pretherapeutic NLR can be used as a predictor for chemosensitivity of thoracic esophageal cancer. Preoperative evaluation based on the clinical N stage and NLR may be easily used in routine clinical practice.
- Open Access
- 12 October 2011
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 6 (1) , 135
Surgical treatment for pulmonary metastases from esophageal carcinoma after definitive chemoradiotherapy: Experience from a single institution
Surgical treatment for pulmonary metastases is known to be a safe and potentially curative procedure for various primary malignancies. However, there are few reports regarding the prognostic role of surgical treatment for pulmonary metastases from esophageal carcinoma, especially after definitive chemoradiotherapy (CRT).
- 12 October 2011
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 6 (1) , 135
Open AccessSurgical treatment for pulmonary metastases from esophageal carcinoma after definitive chemoradiotherapy: Experience from a single institution
Surgical treatment for pulmonary metastases is known to be a safe and potentially curative procedure for various primary malignancies. However, there are few reports regarding the prognostic role of surgical treatment for pulmonary metastases from esophageal carcinoma, especially after definitive chemoradiotherapy (CRT).